125 related articles for article (PubMed ID: 35021072)
1. Fine-tuning of MEK signaling is pivotal for limiting B and T cell activation.
Houde N; Beuret L; Bonaud A; Fortier-Beaulieu SP; Truchon-Landry K; Aoidi R; Pic É; Alouche N; Rondeau V; Schlecht-Louf G; Balabanian K; Espéli M; Charron J
Cell Rep; 2022 Jan; 38(2):110223. PubMed ID: 35021072
[TBL] [Abstract][Full Text] [Related]
2. ERK1/2 can feedback-regulate cellular MEK1/2 levels.
Hong SK; Wu PK; Karkhanis M; Park JI
Cell Signal; 2015 Oct; 27(10):1939-48. PubMed ID: 26163823
[TBL] [Abstract][Full Text] [Related]
3. A Mek1-Mek2 heterodimer determines the strength and duration of the Erk signal.
Catalanotti F; Reyes G; Jesenberger V; Galabova-Kovacs G; de Matos Simoes R; Carugo O; Baccarini M
Nat Struct Mol Biol; 2009 Mar; 16(3):294-303. PubMed ID: 19219045
[TBL] [Abstract][Full Text] [Related]
4. The Leydig cell MEK/ERK pathway is critical for maintaining a functional population of adult Leydig cells and for fertility.
Yamashita S; Tai P; Charron J; Ko C; Ascoli M
Mol Endocrinol; 2011 Jul; 25(7):1211-22. PubMed ID: 21527500
[TBL] [Abstract][Full Text] [Related]
5. Functional redundancy of the kinases MEK1 and MEK2: Rescue of the Mek1 mutant phenotype by Mek2 knock-in reveals a protein threshold effect.
Aoidi R; Maltais A; Charron J
Sci Signal; 2016 Jan; 9(412):ra9. PubMed ID: 26814233
[TBL] [Abstract][Full Text] [Related]
6. Aberrant extracellular signal-regulated kinase (ERK)1/2 signalling in suicide brain: role of ERK kinase 1 (MEK1).
Dwivedi Y; Rizavi HS; Zhang H; Roberts RC; Conley RR; Pandey GN
Int J Neuropsychopharmacol; 2009 Nov; 12(10):1337-54. PubMed ID: 19835659
[TBL] [Abstract][Full Text] [Related]
7. RNAi-mediated MEK1 knock-down prevents ERK1/2 activation and abolishes human hepatocarcinoma growth in vitro and in vivo.
Gailhouste L; Ezan F; Bessard A; Frémin C; Rageul J; Langouët S; Baffet G
Int J Cancer; 2010 Mar; 126(6):1367-77. PubMed ID: 19816936
[TBL] [Abstract][Full Text] [Related]
8.
Beuret L; Fortier-Beaulieu SP; Rondeau V; Roy S; Houde N; Balabanian K; Espéli M; Charron J
Front Cell Dev Biol; 2021; 9():639022. PubMed ID: 34386488
[TBL] [Abstract][Full Text] [Related]
9. Ribonucleotide reductase small subunit p53R2 suppresses MEK-ERK activity by binding to ERK kinase 2.
Piao C; Jin M; Kim HB; Lee SM; Amatya PN; Hyun JW; Chang IY; You HJ
Oncogene; 2009 May; 28(21):2173-84. PubMed ID: 19398949
[TBL] [Abstract][Full Text] [Related]
10. Germline mutations of MEK in cardio-facio-cutaneous syndrome are sensitive to MEK and RAF inhibition: implications for therapeutic options.
Senawong T; Phuchareon J; Ohara O; McCormick F; Rauen KA; Tetsu O
Hum Mol Genet; 2008 Feb; 17(3):419-30. PubMed ID: 17981815
[TBL] [Abstract][Full Text] [Related]
11. Rapamycin induces mitogen-activated protein (MAP) kinase phosphatase-1 (MKP-1) expression through activation of protein kinase B and mitogen-activated protein kinase kinase pathways.
Rastogi R; Jiang Z; Ahmad N; Rosati R; Liu Y; Beuret L; Monks R; Charron J; Birnbaum MJ; Samavati L
J Biol Chem; 2013 Nov; 288(47):33966-33977. PubMed ID: 24126911
[TBL] [Abstract][Full Text] [Related]
12. Crucial requirement of ERK/MAPK signaling in respiratory tract development.
Boucherat O; Nadeau V; Bérubé-Simard FA; Charron J; Jeannotte L
Development; 2014 Aug; 141(16):3197-211. PubMed ID: 25100655
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf.
Marzec M; Kasprzycka M; Liu X; Raghunath PN; Wlodarski P; Wasik MA
Oncogene; 2007 Feb; 26(6):813-21. PubMed ID: 16909118
[TBL] [Abstract][Full Text] [Related]
14. Selective role for Mek1 but not Mek2 in the induction of epidermal neoplasia.
Scholl FA; Dumesic PA; Barragan DI; Harada K; Charron J; Khavari PA
Cancer Res; 2009 May; 69(9):3772-8. PubMed ID: 19383924
[TBL] [Abstract][Full Text] [Related]
15. MEK1/2 inhibitors in the treatment of gynecologic malignancies.
Miller CR; Oliver KE; Farley JH
Gynecol Oncol; 2014 Apr; 133(1):128-37. PubMed ID: 24434059
[TBL] [Abstract][Full Text] [Related]
16. MEK1 and MEK2 differentially control the duration and amplitude of the ERK cascade response.
Kocieniewski P; Lipniacki T
Phys Biol; 2013 Jun; 10(3):035006. PubMed ID: 23735655
[TBL] [Abstract][Full Text] [Related]
17. Differential regulation of mitogen-activated protein/ERK kinase (MEK)1 and MEK2 and activation by a Ras-independent mechanism.
Xu S; Khoo S; Dang A; Witt S; Do V; Zhen E; Schaefer EM; Cobb MH
Mol Endocrinol; 1997 Oct; 11(11):1618-25. PubMed ID: 9328344
[TBL] [Abstract][Full Text] [Related]
18. Small GTPase RBJ mediates nuclear entrapment of MEK1/MEK2 in tumor progression.
Chen T; Yang M; Yu Z; Tang S; Wang C; Zhu X; Guo J; Li N; Zhang W; Hou J; Liu H; Han C; Liu Q; Gu Y; Qian C; Wan T; Cui L; Zhu M; Zheng W; Cao X
Cancer Cell; 2014 May; 25(5):682-96. PubMed ID: 24746703
[TBL] [Abstract][Full Text] [Related]
19. A mortalin/HSPA9-mediated switch in tumor-suppressive signaling of Raf/MEK/extracellular signal-regulated kinase.
Wu PK; Hong SK; Veeranki S; Karkhanis M; Starenki D; Plaza JA; Park JI
Mol Cell Biol; 2013 Oct; 33(20):4051-67. PubMed ID: 23959801
[TBL] [Abstract][Full Text] [Related]
20. Mitogen-activated protein kinase (MAPK)-docking sites in MAPK kinases function as tethers that are crucial for MAPK regulation in vivo.
Grewal S; Molina DM; Bardwell L
Cell Signal; 2006 Jan; 18(1):123-34. PubMed ID: 15979847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
